The purpose of the study is to understand how aspirin affects the chances of cancer coming back and the overall survival of patients with stage II and III colon cancer. Participants in the study will take either aspirin or a placebo every day for up to five years. The study is designed to be “double-blind,” meaning neither the participants nor the researchers know who is receiving aspirin and who is receiving the placebo, to ensure unbiased results.

Throughout the study, researchers will monitor the participants’ health to see if the cancer returns and to track their overall survival. The main goal is to see if taking aspirin can help improve survival rates over five years. The study will also look at how long patients remain free from cancer and how long they can continue the treatment without any issues. This research aims to provide valuable insights into the potential benefits of aspirin for patients who have undergone surgery for colon cancer.

Participants in the study will receive either the intensive FOLFOXIRI treatment or the standard CAPOX treatment. The study will monitor the effects of these treatments over a period of time to determine which is more effective in reducing ctDNA levels. The trial will also look at the overall health and quality of life of the participants during and after the treatment. The study is expected to continue until the end of 2026.

The trial will assess the proportion of patients who show no detectable ctDNA after treatment, comparing the results between the two treatment groups. Additionally, the study will evaluate the disease-free survival rates of participants, which means the length of time they remain free from cancer after treatment. The trial will also monitor any side effects experienced by participants and compare the quality of life between those receiving FOLFOXIRI and those receiving CAPOX.

The study is divided into two parts. In the first part, patients receive adjuvant therapy, which is additional treatment given after surgery to help prevent cancer from returning. This part of the study compares the effectiveness of FOLFOXIRI against FOLFOX/CAPOX, and for a specific group of patients with HER2-positive/RAS wild-type colon cancer, it compares FOLFOX plus Trastuzumab and Tucatinib. The second part of the study focuses on post-adjuvant treatment, which is given after the initial adjuvant therapy. In this phase, the study examines the effects of Trifluridine/Tipiracil compared to observation, meaning no additional treatment, in patients who still have positive ct-DNA after completing their initial therapy.

Throughout the study, patients will receive their treatments either orally or through intravenous use, depending on the medication. The trial will monitor the rate at which ct-DNA is cleared from the blood, as well as any side effects experienced by participants. The goal is to find the most effective treatment strategy to reduce the risk of cancer recurrence in patients with resected colon cancer. The study is expected to continue until 2028, providing valuable insights into the management of colon cancer post-surgery.

Participants in the study will be randomly assigned to receive either the chemotherapy treatment with *capecitabine* or a follow-up without additional therapy. The study will monitor the participants over time to see if the cancer returns, spreads, or if a new cancer develops. The study will also look at overall survival, which means the length of time patients live after the treatment, regardless of whether the cancer comes back. The study will continue to collect data on the participants’ health and any side effects they may experience from the treatment.

The trial will also explore other factors, such as the level of ctDNA before any recurrence of cancer and how it changes during or after chemotherapy. This information will help researchers understand the relationship between ctDNA levels and the risk of cancer returning or spreading. The study is expected to provide valuable insights into the best treatment approaches for patients with stage II colon and rectal cancer.

Participants in the study will be randomly assigned to receive either aspirin or a placebo, which is a tablet that looks like aspirin but does not contain any active medication. This is done to compare the effects of aspirin against no active treatment. The study is designed to be “double-blind,” meaning neither the participants nor the researchers know who is receiving aspirin and who is receiving the placebo, to ensure unbiased results.

The main goal of the study is to see if aspirin can improve the five-year overall survival rate, which is the percentage of people who are still alive five years after treatment. Additionally, the study will look at other outcomes such as disease-free survival, which measures the time patients remain free from cancer, and time to treatment failure, which tracks how long the treatment remains effective. The trial is expected to continue until the end of 2027.

The purpose of this study is to see how well this combination of treatments works when given before surgery to remove the cancer. The study will involve patients receiving these treatments over a period of time before they undergo surgery. During the study, some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment. The study aims to understand if this combination can improve the response of the cancer to treatment before surgery.

Participants in the study will receive the treatments in a controlled setting, and their health will be monitored closely by medical professionals. The study will help researchers learn more about the potential benefits and any side effects of using Ipilimumab, Nivolumab, and high-dose Vitamin C together in treating this type of colon cancer. This research is important for developing new ways to treat cancer and improve outcomes for patients.

Participants in the study will receive either Tofranil or a placebo, which looks like the medication but does not contain the active ingredient. The study will observe the effects of Tofranil on the cancer cells, particularly focusing on changes in the way the cells look and behave under a microscope. This includes examining the tumor’s structure and the presence of certain immune cells around the tumor. The study will also measure the levels of tumor DNA in the blood and the amount of Fascin1 protein in the tissue removed during surgery.

The trial will take place over a period of time, with some patients being observed for 2-6 weeks and others for 3-6 months, depending on their treatment plan. The goal is to understand if Tofranil can help change the characteristics of the cancer cells, potentially leading to better treatment outcomes for patients with these types of cancer.